cbc.ca (© Copyright: (C) Canadian Broadcasting Corporation, http://www.cbc.ca/aboutcbc/discover/termsofuse.html#Rss)
Updated: Wed, 06 Aug 2014 23:27:55 GMT | By The Associated Press, cbc.ca

Experimental Ebola drug ZMapp raises issues of fair access



A scientist separates blood cells from plasma cells to isolate any Ebola RNA in order to test for the virus at the European Mobile Laboratory in Gueckedou April 3, 2014. Hiccups, say doctors in this remote corner of Guinea, are the final tell-tale sign of infection by the Ebola virus that has killed more than 100 people since an outbreak began this year. Then come profuse bleeding, circulatory shock and death. In total, 98 people are thought to have died from the disease in Guinea and 10 more in neighbouring Liberia, according to aid workers and governments. A market town of 220,000 people near the Liberia and Sierra Leone borders, Gueckedou's makeshift clinic is on the front line of Guinea's battle to contain its first outbreak of the haemorrhagic fever, normally found in Central Africa. Picture taken April 3, 2014. REUTERS/Misha Hussain (© GUINEA - Tags: HEALTH SOCIETY)

A scientist separates blood cells from plasma cells to isolate any Ebola RNA in order to test for the virus at the European Mobile Laboratory in Gueckedou April 3, 2014. Hiccups, say doctors in this remote corner of Guinea, are the final tell-tale sign of infection by the Ebola virus that has killed more than 100 people since an outbreak began this year. Then come profuse bleeding, circulatory shock and death. In total, 98 people are thought to have died from the disease in Guinea and 10 more in neighbouring Liberia, according to aid workers and governments. A market town of 220,000 people near the Liberia and Sierra Leone borders, Gueckedou's makeshift clinic is on the front line of Guinea's battle to contain its first outbreak of the haemorrhagic fever, normally found in Central Africa. Picture taken April 3, 2014. REUTERS/Misha Hussain (GUINEA - Tags: HEALTH SOCIETY) - RTR3KEK9 Misha Hussain/Reuters

The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak — things like more rapidly identifying and isolating the sick.

The World Health Organization is convening a meeting of medical ethicists next week to examine what it calls "the responsible thing to do" about whatever supplies eventually may become available of a medicine that's never been tested in people.

-

How Canada's Ebola preparations have 'led the world'

-

MAP | Ebola's deadly spread

At least one country involved in the outbreak is interested in the drug. Nigeria's health minister, Onyenbuchi Chukwu, said at a news conference that he had asked the U.S. Centers for Disease Control and Prevention about access. CDC Director Tom Frieden "conveyed there are virtually no doses available" but basic supportive care can work, a CDC spokesman said Wednesday.

There is no proven treatment or vaccine for Ebola, which so far has infected more than 1,700 people and killed more than 930 in West Africa in what has become the worst outbreak of this viral hemorrhagic fever.

"How many times have we found magic therapies that ended up ... doing more harm than good?" cautioned University of Minnesota professor Michael Osterholm, who advises the U.S. government on infectious disease threats.

"Vaccine and drug treatment right now is not going to be the main way you bring this to a stop," he added.

U.S. President Barack Obama said Tuesday there wasn’t enough information available on the new drug to consider fast-tracking it, and said the U.S. and its health partners are focused on controlling and containing the disease.

Unclear if new treatment works

Scientists stress that there's no way to tell if the experimental drug ZMapp really made a difference for two American aid workers infected while working in Liberia.

"We don't even know if it works," stressed Dr. Anthony Fauci of the National Institutes of Health, which helped fund research that led to the drug's development.

The drug is a cocktail of three antibodies engineered to recognize Ebola and bind to infected cells so that the immune system can kill them.

People's immune systems make antibodies to fight off various diseases, and attempts to cull those antibodies — from the blood of people who survive an illness, or from animals — date back to the 19th century and early diphtheria treatment. Using modern techniques to fight Ebola, scientists culled antibodies from laboratory mice, Fauci said, and ZMapp's maker now grows the antibodies in tobacco plants and then purifies them.

Fauci said the manufacturer has told the government that it would take two to three months to produce even "a modest amount." So the NIH is exploring ways to ramp up production, necessary to attempt formal testing or to consider more so-called compassionate use.

"Everybody's trying to speed things up," he said.

Experimental blood test also in the works

To help improve diagnosis in affected countries, the Food and Drug Administration on Wednesday authorized emergency use of an experimental blood test to detect Ebola. Early symptoms — fever, vomiting and diarrhea — can be confused with other illnesses. The test was developed by the Defence Department, and is only for use in DOD-designated laboratories.

This week, the WHO is convening an emergency committee to determine if the outbreak warrants being declared a "public health emergency of international concern," meaning it poses significant risk to other countries and requires more of an international response.

The WHO said that particularly in Liberia, health officials face community resistance from residents who fear going to the hospital and secretly care for ill loved ones at home, thus exposing themselves. Ebola is transmitted only through direct contact with the blood and other bodily fluids of someone who is sick.

But health care workers have to recognize the virus, too. Authorities in Nigeria have acknowledged that they didn't immediately suspect Ebola in the first known patient to travel to that country.

"The bottom line with Ebola is we know how to stop it: traditional public health," said CDC's Frieden said Wednesday: Finding and isolating patients, finding and educating who's been in contact with them and strict hospital infection control.

"Do those things with meticulous care and Ebola goes away," he said.

more video